期刊
CANCERS
卷 12, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/cancers12113328
关键词
-
类别
资金
- European Regional Development Fund-Project ENOCH [CZ.02.1.01/0.0/0.0/16_019/0000868]
- Grant Agency of the Masaryk University [MUNI/A/1127/2019]
- Ministry of Health of the Czech Republic [NV18-07-00073, 17-28518A, 18-08-00245]
- American Brain Tumor Association
- MSKCC Support Grant [P30 CA008748]
- Ministry of Education, Youth and Sports of the Czech Republic [CZ.02.1.01/0.0/0.0/15_003/0000469, 02.1.01/0.0/0.0/18_046/0015975]
- CETOCOEN EXCELLENCE Teaming 2 project
- Horizon2020 [857560]
Trophoblast cell surface antigen 2 (Trop2) is a widely expressed glycoprotein and an epithelial cell adhesion molecule (EpCAM) family member. Although initially identified as a transmembrane protein, other subcellular localizations and processed forms were described. Its congenital mutations cause a gelatinous drop-like corneal dystrophy, a disease characterized by loss of barrier function in corneal epithelial cells. Trop2 is considered a stem cell marker and its expression associates with regenerative capacity in various tissues. Trop2 overexpression was described in tumors of different origins; however, functional studies revealed both oncogenic and tumor suppressor roles. Nevertheless, therapeutic potential of Trop2 was recognized and clinical studies with drug-antibody conjugates have been initiated in various cancer types. One of these agents, sacituzumab govitecan, has been recently granted an accelerated approval for therapy of metastatic triple-negative breast cancer. In this article, we review the current knowledge about the yet controversial function of Trop2 in homeostasis and pathology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据